Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until December 7, 2036, barring specific contingencies. While this agreement eliminates generic entry risk from Teva for over a decade, Aurinia’s legal defense continues against other generic applicants, including Dr. Reddy’s and Sandoz.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH): Focused Commercial Execution and Pure Cash Flow
Aurinia’s business relies entirely on LUPKYNIS, and financial performance remains exceptionally strong. In Q2 2026, total revenue reached $83.2 million (up 19% YoY), while six-month revenue reached $160.9 million (up 21% YoY). Net income jumped 74% in Q2 to $37.4 million ($0.28 per diluted share), with first-half profits hitting $71.8 million. Free cash generation is robust; operating cash flows expanded 87% year-to-date to $85.1 million, bringing its debt-free cash balance to $443.1 million. Management reaffirmed its full-year 2026 revenue guidance of $315 million to $325 million.
Teva Pharmaceuticals Industries Limited (NYSE:TEVA): Pivot to Growth vs. Generic Drag
Teva operates on a vastly larger, highly diversified scale. In Q2 2026, total revenue slipped 1% YoY to $4.1 billion, as generic revenues dropped 15% due to generic Revlimid competition. However, its key innovative brand portfolio (AUSTEDO, AJOVY, and UZEDY) surged 43% YoY to over $1 billion, prompting management to raise full-year revenue guidance to $16.5–$16.85 billion. Non-GAAP earnings per share fell to $0.02 as the company logged a $576 million net loss, driven by upfront costs from acquiring Emalex Biosciences to bolster its late-stage CNS pipeline.
Financial Comparison: Clean Growth vs. Diversified Scale
Comparing financials, Aurinia is currently outperforming on bottom-line margin expansion and balance sheet health. Aurinia boasts a high profit conversion with zero debt and expanding operating cash flows, whereas Teva carries substantial leverage and generic top-line volatility, though it commands massive market share and multi-billion-dollar brand pipelines.
Bull and Bear Cases
The bull case for Aurinia centers on clear runway visibility for LUPKYNIS into 2036 following the Teva settlement, supported by heavy share repurchases. The bear case lies in single-product concentration risk and ongoing litigation against remaining ANDA filers.
Teva’s bull case hinges on branded neuroscience engines replacing legacy generic declines. Its bear case stems from debt obligations, generic pricing pressures, and regulatory execution risks on late-stage assets.
Insider Monkey’s Hedge Fund Data Analysis
Hedge fund sentiment showed stable institutional ownership in Aurinia Pharmaceuticals and growing interest in Teva Pharmaceuticals during Q2 2026. Aurinia was held by 28 hedge funds, unchanged from Q1. Tang Capital Management remained the largest holder with 13.04 million shares valued at approximately $221.36 million after increasing its position by 7%, while Arrowstreet Capital held 3.26 million shares valued at approximately $55.39 million.
Teva Pharmaceuticals saw institutional participation increase, with 54 hedge funds holding positions in Q2 2026 compared with 52 in Q1. Rubric Capital Management remained a leading holder with 15.58 million shares valued at approximately $527.68 million after increasing its stake by 3%. Alyeska Investment Group also increased its position by 14% to 6.26 million shares valued at approximately $212.01 million.
Conclusion: What Investors Should Watch Next
Looking ahead, investors in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) must track District Court rulings involving remaining generic challengers like Dr. Reddy’s and Hikma to confirm complete patent protection. For Teva Pharmaceuticals Industries Limited (NYSE:TEVA), the focus shifts to FDA action on olanzapine LAI in Q4 2026 and generic Revlimid revenue stabilization.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center